Navigation Links
Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
Date:9/15/2008

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will move on to the next phase to validate targets for inflammatory bowel disease (IBD) using Cequent's proprietary TransKingdom RNA interference [tkRNAi(TM)] technology in animal models. Specific payment terms and targets were not disclosed.

"IBD is actually a spectrum of diseases, and the power of RNAi is that you could potentially design therapeutics specifically to target the individual forms of the disease," said Cequent President and CEO, Peter Parker. "When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our milestone goal, which we accomplished, was to winnow the targets down to three that we will further validate in in vivo animal trials before Cequent selects the single target to be the subject of the Option agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human Papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many devastating diseases."

Said Steven Tregay, PhD, a managing director of Novartis Option Fund, "We are impressed with both the quality and speed of the work that Cequent is doing on the IBD program -- as well as the potential of their tkRNAi platform. Creating compounds to address eight targets and completing in vitro screening in only nine months would have been virtually impossible with traditional small-molecule-based drug discovery technologies. We're pleased to release the milestone payment to Cequent, and look forward to our continued relationship both as venture
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
3. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
4. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
5. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
6. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
7. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
8. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
9. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
10. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
11. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... FamilyFarms Group is pleased to announce its ... Farms, received the 2015 Tomorrow’s Top Producer Horizon Award. ... of 35, who has demonstrated excellence in the business ... the Tomorrow's Top Producer Horizon Award. Every year I ... Award and learning from their experiences. It is truly ...
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... white paper titled “Avanta AC™ Advanced Ceramics ... online. This white paper outlines the challenges ... nanometer scale, as well as the advantages ... ceramic nanopowders are critical to a variety ...
... June 25 Cell Biosciences, Inc., a,provider of ... researchers, today announced three important additions to,its management ... Chief Executive Officer. From 1998,through 2007, Mr. Harkness ... where he helped build the company into a ...
... Israel and JERSEY CITY, New Jersey, June 25, Rosetta Genomics, ... Company,s CFO for the last two and a half,years, has ... for a new Chief Financial Officer. Mr. Kazaz is expected ... the company in its search and,during the transition of his ...
Cached Biology Technology: SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2Cell Biosciences Announces New Leadership 2Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer 2Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer 3
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... Park Zoo applauds the federal government,s announcement today that it ... United States as an endangered species. A decision to do ... which is endangered in the wild. According the ... severely endangered and could become extinct within 10 to 50 ...
... is overheated, imagine what goes on inside a vertebrate embryo. ... a battle with consequences much more dire than whether the ... frogs or chickens) will have a forebrain. In ... Genes & Development , Salk Institute investigators led by ...
... that dendritic cells in the liver have a protective ... over-the-counter pain reliever and fever reducer for adults and ... issue of the journal Hepatology . ... role in transforming and filtering chemicals from the body. ...
Cached Biology News:Lincoln Park Zoo applauds government decision to consider reclassifying chimpanzees as endangered 2The battle of the morphogens: How to get ahead in the nervous system 2The battle of the morphogens: How to get ahead in the nervous system 3Dendritic cells in liver protect against acetaminophen toxicity 2
Goat polyclonal to Lipocalin 2...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
... encodes two unrelated proteins both of which ... cell cycle in a p53-dependent manner. p14^ARF^ ... degradation of mdm2 proteinrequired for mdm2 modification ... This interaction is mediated by the exon ...
... Hinge Region By immunoblotting the antibody reacts ... reacts with free MMP-2 or MMP-2 bound ... aqueous glycerol solution Solution in 0.01 ... 50% glycerol and 15 mM sodium azide. ...
Biology Products: